Sector News

Medivir plans split into two companies

August 31, 2016
Life sciences

Medivir said today it will split by year’s end into two companies—one focused on developing its drug portfolio, the other focused on commercial operations.

“The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio,” Medivir said in a statement.

The commercial company will oversee the company’s 15 marketed drugs. One is the hepatitis C treatment Olysio® (simeprevir), an NS3/4A protease inhibitor jointly developed by Medivir and Johnson & Johnson’s Janssen R&D Ireland.

Another is Adasuve® (loxapine), an inhaled medicine for acute treatment of agitation associated with schizophrenia or bipolar I disorder. Medivir launched Adasuve in Sweden, Norway, Finland, and Denmark in 2013 under license from Ferrer—which earlier this year acquired Adasuve developer Alexza Pharmaceuticals.

Also to be marketed by the commercial company are the 13 drugs that form Medivir’s Nordic Brands Portfolio, which the company obtained through the acquisition of BioPhausia in 2011. The 13 have indications related to central nervous system (CNS), cardiovascular system, gout, musculoskeletal system, pain, respiratory system, stomach/intestine, and zinc deficiency.

The commercial company will have a separate public listing on the First North Premium exchange.

The R&D-focused company will develop Medivir’s pipeline, whose sole clinical candidate is MIV-711, a cathepsin K inhibitor indicated for the treatment of osteoarthritis. MIV-711 is the subject of a Phase IIa trial assessing the candidate in patients with moderate knee osteoarthritis. Data is expected to be available in the third quarter of 2017.

The company’s preclinical candidates include a nucleotide DNA polymerase inhibitor indicated for hepatocellular carcinoma and a respiratory syncytial virus (RSV) fusion protein inhibitor indicated for RSV infection. Discovery-phase candidates include an human immunodeficiency virus (HIV) protease inhibitor being developed in partnership with Janssen.

Earlier this month, Medivir sold rights to another preclinical candidate—MIV-802, a nucleotide-based polymerase inhibitor indicated for hepatitis C virus—to Trek Pharmaceuticals for an undisclosed price. Those rights covered most of the world, except China, Taiwan, Hong Kong, and Macau.

Medivir said it will provide additional details on the corporate split at a future capital markets day.

Source: GEN

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.